Testing a treatment to help clear genital high-risk HPV
Part of Infections clinical trials.
This trial studies 2LPAPI® to see if it helps the body clear high-risk HPV infections in the cervix. It may be an option if you have a current HPV infection with mild/early abnormal cervical findings and can complete follow-up for about a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 25–45
- You are not pregnant or breastfeeding, and you can use effective birth control during the study
- Your recent cervical tests show either normal or mild changes (no HSIL, and no CIN II/III)
- You have a current high-risk HPV infection based on today’s cervical sample
- You can stay in follow-up for 12 months and are able to attend study visits
- You should not have had HPV vaccination in the last month or joined another study in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called ACU-D1 for treating high-grade precancerous lesions caused by HPV in the vulvar or perianal area. The goal is to see if the gel can help clear these lesions in people living with HIV.
This trial tests whether a vaccine against HPV can help prevent pre-cancerous lesions from coming back after you've had them. It's for people who have had high-grade pre-cancerous lesions but haven't yet been treated for them.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
This trial tests an antibacterial liquid (Paiteling®) to see if it can clear a persistent high-risk HPV infection of the cervix. It may be an option for women whose HPV has lasted 2 years or more and whose cervical biopsy shows only mild changes.
This study tests a new vaginal medication (Dysplasix) to treat mild cervical cell changes caused by high-risk HPV. The goal is to see if this treatment can help your body clear the virus and prevent these changes from getting worse.
This trial tests whether Papillex, a supplement, can help clear abnormal cervical cells caused by HPV. You may be eligible if you have HPV and abnormal cell changes that haven't been treated recently.
Hear when a new Human Papilloma Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.